Get the Stockscreener App
17.43
24.23%
3.40
After Hours:
17.55
0.12
+0.69%
Terns Pharmaceuticals Inc stock is traded at $17.43, with a volume of 14.15M.
It is up +24.23% in the last 24 hours and up +111.79% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$14.03
Open:
$15.5
24h Volume:
14.15M
Relative Volume:
7.08
Market Cap:
$1.53B
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-13.20
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
+102.91%
1M Performance:
+111.79%
6M Performance:
+398.00%
1Y Performance:
+145.49%
1-Day Range:
$15.50
$18.75
1-Week Range:
$7.8691
$18.75
52-Week Range:
$1.865
$18.75
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
17.43 | 1.23B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharma (NASDAQ: TERN) awards 252,500 options under Nasdaq Rule 5635(c)(4) - Stock Titan
Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday - Benzinga
Terns Pharma (TERN) Receives Price Target Raise to $28 by Truist - GuruFocus
Truist Financial Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $28 - 富途牛牛
Terns Pharmaceuticals stock price target raised to $22 at BMO on strong ASH data - Investing.com Nigeria
Terns Pharmaceuticals stock extends gain after positive CML drug data - Investing.com
Terns Pharmaceuticals stock hits 52-week high at 16.41 USD - Investing.com
Terns Pharma (TERN): Barclays Raises Price Target by 92.86% | TE - GuruFocus
Mizuho Boosts Price Target on Terns Pharmaceuticals to $32 From $9, Keeps Outperform Rating - MarketScreener
Terns reports 64% MMR rate in phase 1 CML trial with TERN-701 - Investing.com Australia
Terns Pharmaceuticals (TERN) Upgraded with Increased Price Targe - GuruFocus
Terns Pharmaceuticals (TERN) Upgraded with Increased Price Target Following Promising Data - GuruFocus
Terns Pharmaceuticals stock rating upgraded to Buy by H.C. Wainwright - Investing.com
Terns Pharma (TERN) Upgraded to Buy by HC Wainwright & Co. | TER - GuruFocus
Terns Pharmaceuticals stock price target raised by Truist on CML drug data - Investing.com South Africa
William Blair Upgrades Terns Pharmaceuticals (TERN) - Nasdaq
Price momentum metrics for Terns Pharmaceuticals Inc. explainedEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Relative strength of Terns Pharmaceuticals Inc. in sector analysisMarket Performance Recap & Weekly Return Optimization Alerts - newser.com
Terns Pharmaceuticals (TERN) Is Up 74.1% After Positive Phase 1 TERN-701 Data in CML Patients - Yahoo Finance
Combining price and volume data for Terns Pharmaceuticals Inc.Dollar Strength & Growth Oriented Trade Recommendations - newser.com
How sentiment analysis helps forecast Terns Pharmaceuticals Inc.Quarterly Growth Report & Verified Short-Term Trading Plans - newser.com
What does recent volatility data suggest for Terns Pharmaceuticals Inc.Market Risk Analysis & Reliable Price Action Trade Plans - newser.com
Terns Pharmaceuticals (TERN) Pivots After TERN-601 Setback Can a Focus on Oncology Redefine Its Future? - simplywall.st
After GLP-1 drug falters, Terns Pharmaceuticals shifts focus to cancerBizwomen - The Business Journals
Oppenheimer raises Terns Pharmaceuticals stock price target to $24 on promising leukemia drug data By Investing.com - Investing.com South Africa
Terns Pharma (TERN) Upgraded to Outperform by William Blair | TE - GuruFocus
Oppenheimer raises Terns Pharmaceuticals stock price target to $24 on promising leukemia drug data - Investing.com Australia
William Blair upgrades Terns Pharmaceuticals stock rating to Outperform By Investing.com - Investing.com South Africa
Biotech Deals And Breakthroughs Spark Heavy Trading Across Markets - Finimize
Pharmaceutical Stocks To Add to Your WatchlistNovember 3rd - MarketBeat
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades - Benzinga
Terns reports 64% MMR rate in phase 1 CML trial with TERN-701 By Investing.com - Investing.com South Africa
William Blair upgrades Terns Pharmaceuticals stock rating to Outperform - Investing.com
Terns Pharmaceuticals (TERN) Upgraded After Promising Clinical T - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy By Investing.com - Investing.com Philippines
Terns Pharmaceuticals (TERN) Presents Promising Data from CARDINAL Trial - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy - Investing.com
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting - The Manila Times
Terns Pharmaceuticals Announces Positive Data from CARDINAL Trial - TradingView
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML ... - Bluefield Daily Telegraph
Will Terns Pharmaceuticals Inc. stock recover after recent dropPortfolio Return Report & Consistent Profit Trade Alerts - newser.com
Sector ETF performance correlation with Terns Pharmaceuticals Inc.Trade Entry Summary & Low Risk Entry Point Tips - newser.com
Applying Wyckoff theory to Terns Pharmaceuticals Inc. stockMarket Trend Review & High Conviction Buy Zone Picks - newser.com
Should you hold or exit Terns Pharmaceuticals Inc. nowTrade Ideas & Intraday High Probability Setup Alerts - newser.com
Real time breakdown of Terns Pharmaceuticals Inc. stock performanceQuarterly Performance Summary & Target Return Focused Stock Picks - newser.com
How hedge fund analytics apply to Terns Pharmaceuticals Inc. stockWeekly Investment Report & Long-Term Safe Return Strategies - newser.com
Is Terns Pharmaceuticals Inc. still worth holding after the dipJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
How Terns Pharmaceuticals Inc. stock reacts to Fed rate cutsMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Advanced analytics toolkit walkthrough for Terns Pharmaceuticals Inc.Portfolio Value Report & Real-Time Market Trend Scan - newser.com
What Wall Street predicts for Terns Pharmaceuticals Inc. stock priceM&A Rumor & Long-Term Safe Return Strategies - newser.com
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):